Latest Articles

The Friedman test can be used to compare repeated measures or samples, such as following a person's biological functions over time. In this article, we consider its assumptions, when to use it and go through a worked example.

The four main considerations that any leader should take into account to successfully implement AI in their organization are explored here.

In this article, we discuss how a deep learning framework can specifically address real-world challenges to enhance site selection while seeking to improve trial diversity.

From AI's transformative role in drug discovery and CRISPR breakthroughs to the rise of biosimilars and real-world data. Learn how these innovations are reshaping pharma and driving progress in 2024.

This article explores the challenges and strategies involved in transitioning to automated cryogenic storage systems. From assessing current infrastructure to gaining organizational buy-in and selecting appropriate containers, follow these steps to help ensure a successful transition to automated cryogenic storage.

If you want to compare means of continuous variables between two groups or to a hypothesized value, you might need a z test. In this article, we explore the two types of z test, assumptions of the test, interpretation and a worked example.

Technology Networks spoke to Dr. Ishwar Singh to learn more about the challenges of drug-resistant infections, the discovery of teixobactin and the benefits of synthetic antibodies.

This article explores the need to deregulate certain psychedelic drugs, including MDMA and psilocybin, which could help people living with PTSD and treatment-resistant depression as pharmaceutical treatments to retrain neural pathways and improve these conditions.

In this article, we will explore the theory, assumptions and interpretation of Pearson’s correlation, including a worked example of how to calculate Pearson’s correlation coefficient, often referred to as Pearson’s r.

Dr. Nancy Klimas, director of the Institute for Neuro-Immune Medicine at Nova Southeastern University, explains the great potential of monoclonal antibodies in treating long COVID.